Arterion develops biomaterials based on microbially derived cellulose.
Encubator Portfolio Company from 2006.
Arterion’s technology is based on microbial-derived cellulose, a unique material that, by controlling the life conditions of the bacteria Acetobacter xylinum, can be used to manufacture implantable and biocompatible biomaterials of any shape and size. As a first clinical application area, Arterion develops artificial vascular grafts, and a performed in vivo evaluation in sheep has shown a patency period of at least thirteen months.
Related Stories
2010
2009
2008
2007
2006
Henrik Elofsson, Research Manager
Karl Richard Nilsson, CEO
Kristoffer Drotz, Production Manager
Arterion is an Encubator Portfolio Company from GIBBS class of 2006.
Medtech
Paul Gatenholm
Bo Risberg
Aase Bodin
Henrik Bäckdahl
+46 31-44 80 02
Arvid Wallgrens Backe 20, Gothenburg
Solution
Artificial Blood Vessels
The first product will be a pure cellulose vessel, which is to be usedas vascular replacement in patients with circulatory problems. All early verification studies indicate that our cellulose product will have leverage to all known competitors. Arterion is, however, already performing studies where the inner side of the vessel is coated with molecules selectedfrom a number of possible candidates. Thus two additional patents have been exclusively licensed to the company. The vessels are currently manufactured with an internal diameter between 1.5 and 6 mm and with a length up to 17 cm. However, the manufacturing procedure does not limit the production of thinner, wider, or longer vessels.
